Comparing antibody and small-molecule therapies for cancer

被引：623

作者：

Imai, Kohzoh

Takaoka, Akinori

机构：

[1] Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[2] Univ Tokyo, Fac Med, Grad Sch Med, Dept Immunol,Bunkyo Ku, Tokyo 1130033, Japan

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 09期

关键词：

D O I：

10.1038/nrc1913

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.

引用

收藏

页码：714 / 727

页数：14

相关论文

共 163 条

[31]

Ciardiello F, 2000, CLIN CANCER RES, V6, P2053

[32] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[33] Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics [J].

Cohen, LH ;

Pieterman, E ;

van Leeuwen, REW ;

Overhand, M ;

Burm, BEA ;

van der Marel, GA ;

van Boom, JH .

BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1061-1068

[34] Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents [J].

Cragg, MS ;

Glennie, MJ .

BLOOD, 2004, 103 (07) :2738-2743

[35] Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts [J].

Cragg, MS ;

Morgan, SM ;

Chan, HTC ;

Morgan, BP ;

Filatov, AV ;

Johnson, PWM ;

French, RR ;

Glennie, MJ .

BLOOD, 2003, 101 (03) :1045-1052

[36] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[37] Issues and progress with protein kinase inhibitors for cancer treatment [J].

Dancey, J ;

Sausville, EA .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313

[38] Targeting epidermal growth factor receptor - are we missing the mark? [J].

Dancey, JE ;

Freidlin, B .

LANCET, 2003, 362 (9377) :62-64

[39] Tumour stem cells and drug resistance [J].

Dean, M ;

Fojo, T ;

Bates, S .

NATURE REVIEWS CANCER, 2005, 5 (04) :275-284

[40] Complement activation determines the therapeutic activity of rituximab in vivo [J].

Di Gaetano, N ;

Cittera, E ;

Nota, R ;

Vecchi, A ;

Grieco, V ;

Scanziani, E ;

Botto, M ;

Introna, M ;

Golay, J .

JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587

← 1 2 3 4 5 6 7 8 9 10 →